Boron Neutron Capture Therapy Animation
SCIENTIFIC ANIMATION
TAE Life Sciences’ Boron Neutron Capture Therapy (BNCT) is being developed as a non-invasive radiation treatment for the most difficult to treat cancers. It selectively targets cancer cells to spare healthy tissue making it easier to tolerate than other radiation treatments.
We created an animation that explains the mechanism of action (MoA) of BCNT concisely and engagingly, which makes its benefits clear.
The animation can be found on the TAE Life Sciences website to highlight BCNT as a promising new treatment for inoperable, invasive, or radioresistant cancers. A looped section of the animation plays on the homepage making the page visually engaging and establishing a consistent brand identity.
Are you interested in seeing how our award-winning medical animation can help you?
Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.
TESTIMONIALS
‘‘For experts, there’s limited time in which they will interact with this content, so getting a message across quickly is crucial, and this medium does it very well.’’
Product Manager, GSK
‘‘Their turnaround time sets them apart from the rest of the field. The fact they can turnaround lots of comments in a couple of days is impressive, whereas that took weeks with other agencies we worked with. They’re well above the benchmark.’’
Oncology Clinical Liaison, Bristol-Myers Squibb
‘‘It was a combination equally of quality of work but also the comfort and confidence that I knew I would be working with PhDs. They gave me the confidence that they would have the ability to understand. The other companies didn’t have those sorts of people on staff, they were just good animators. That was the area where I felt that I could trust Random42 would deliver.’’
Senior Product Manager, Spectranetics
‘‘I have been to a lot of conferences and I have seen a lot of videos both from competitors and internally – in my eyes it is night and day. The quality Random42 have is not one step ahead, it is far ahead compared to what I have seen before.’’
Product Manager, Amgen
